2-Amino-3-oxo-2-piperidin-1-ylpropanenitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Amino-3-oxo-2-piperidin-1-ylpropanenitrile
• 英文别名: 2-amino-3-oxo-2-piperidin-1-ylpropanenitrile
• 化学式: C₈H₁₃N₃O
• 分子量: 167.21
• InChiKey: JJSMKPNMYXEQAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS
  申请人：AB Science

  公开号：EP2922572A1

  公开（公告）日：2015-09-30
• [EN] USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS<br/>[FR] UTILISATION D'INHIBITEURS/ACTIVATEURS À PETITE MOLÉCULE EN COMBINAISON AVEC DES ANALOGUES DE (DÉSOXY)NUCLÉOSIDE OU DE (DÉSOXY)NUCLÉOTIDE POUR LE TRAITEMENT DU CANCER ET DE MALIGNITÉS HÉMATOLOGIQUES OU D'INFECTIONS VIRALES
  申请人：AB SCIENCE

  公开号：WO2014079709A1

  公开（公告）日：2014-05-30

  The present invention relates to a method for treating patients afflicted with cancer (including hematological malignancies) or viral infections, wherein said patients are under treatment or are to be treated with at least one anticancer or antiviral agent, and in particular (deoxy)nucleotide or (deoxy)nucleoside analog drugs, comprising administering at least one small molecule inhibitor/activator (including ATP competitive inhibitors, signal transduction inhibitors/activators, protein kinase inhibitors/activators, and tyrosine kinase inhibitors/activators) in combination with said (deoxy)nucleotide or (deoxy)nucleoside analog, and wherein said small molecule inhibitor/activator is administered in sufficient amount to modulate deoxynucleotide or deoxynucleoside kinase activity (and in particular deoxycytidine kinase activity) to modulate activation of said (deoxy)nucleotide or (deoxy)nucleoside analog in vivo with a subsequent therapeutically beneficial anticancer or antiviral effect. The combined treatments together comprise a therapeutically effective amount.